帕博利珠单抗后伊匹木单抗或BRAF±MEK抑制剂在晚期黑色素瘤中的抗肿瘤活性:KEYNOTE-006分析
基于III期KEYNOTE-006研究的事后分析,评估晚期黑色素瘤患者在接受帕博利珠单抗后首次后续系统治疗使用伊匹木单抗或BRAF±MEK抑制剂的抗肿瘤活性。结果显示后续伊匹木单抗ORR为15.5%,后续BRAF±MEK抑制剂ORR为30.5%,BRAF±MEK抑制剂初治患者ORR达43.2%,表明两种方案均具有抗肿瘤活性。
要点
- 帕博利珠单抗后序贯伊匹木单抗或BRAF±MEK抑制剂均显示抗肿瘤活性。
- 后续BRAF±MEK抑制剂在初治患者中ORR达43.2%。
- 后续伊匹木单抗在帕博利珠单抗最佳疗效为PD的患者中ORR仅9.7%。
核心结论
- 伊匹木单抗和BRAF±MEK抑制剂作为帕博利珠单抗后的首次后续治疗在晚期黑色素瘤患者中具有抗肿瘤活性。
研究设计与样本
- III期KEYNOTE-006研究的事后分析,纳入接受帕博利珠单抗10 mg/kg每2或3周一次或伊匹木单抗3 mg/kg每3周一次的患者,帕博利珠单抗组汇总分析。
- 分析纳入555例帕博利珠单抗治疗患者,其中103例(18.6%)后续接受伊匹木单抗,59例(10.6%)后续接受BRAF±MEK抑制剂。
主要发现
- 后续伊匹木单抗组既往帕博利珠单抗ORR为17.5%(1例CR,17例PR),79.6%因疾病进展停用帕博利珠单抗,中位OS为21.5个月。
- 后续伊匹木单抗ORR为15.5%,16例缓解中11例持续缓解(8例CR,3例PR),帕博利珠单抗最佳疗效为PD的患者后续伊匹木单抗ORR为9.7%,自伊匹木单抗开始中位OS为9.8个月。
- 后续BRAF±MEK抑制剂组既往帕博利珠单抗ORR为13.5%(8例PR),76.3%因疾病进展停用帕博利珠单抗,中位OS为17.9个月。
- 后续BRAF±MEK抑制剂ORR为30.5%,18例缓解中7例持续缓解(4例CR,3例PR),自BRAF±MEK抑制剂开始中位OS为12.9个月。
- BRAF±MEK抑制剂初治患者后续接受BRAF±MEK抑制剂ORR为43.2%,16例中6例持续缓解(3例CR,3例PR)。
临床怎么用
- 对于帕博利珠单抗治疗后进展的晚期黑色素瘤患者,可考虑伊匹木单抗或BRAF±MEK抑制剂作为后续治疗选择。
- BRAF±MEK抑制剂初治患者后续接受BRAF±MEK抑制剂可能获得较高缓解率。
局限性
- 本分析为事后分析,非预设比较,可能存在选择偏倚。
- 样本量有限,部分亚组患者数量较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antitumor activity of ipilimumab or BRAF ± MEK inhibitors (BRAFi ± MEKi) following pembrolizumab administration in melanoma is poorly characterized. PATIENTS AND METHODS: In the phase III KEYNOTE-006 study, patients with unresectable stage III/IV melanoma received pembrolizumab (10 mg/kg) once every 2 or 3 weeks (Q3W) or ipilimumab (3 mg/kg) Q3W. The current post hoc analysis evaluates outcomes with ipilimumab or BRAFi ± MEKi as first subsequent systemic therapy after pembrolizumab administration and includes patients who completed or discontinued pembrolizumab after one or more dose. Pembrolizumab arms were pooled. RESULTS: At data cut-off (4 December 2017), median follow-up was 46.9 months. Of 555 pembrolizumab-treated patients, first subsequent therapy was ipilimumab for 103 (18.6%) and BRAFi ± MEKi for 59 (10.6%) [33 received BRAFi + MEKi, 26 BRAFi alone; 37 (62.7%) were BRAFi ± MEKi naïve]. In the subsequent ipilimumab group, ORR with previous pembrolizumab was 17.5% [1 complete response (CR); 17 partial response (PR)]; 79.6% had discontinued pembrolizumab due to progressive disease (PD); median overall survival (OS) was 21.5 months. ORR with subsequent ipilimumab was 15.5%; 11/16 responses (8 CRs; 3 PRs) were ongoing. ORR with subsequent ipilimumab was 9.7% for patients with PD as best response to pembrolizumab. Median OS from ipilimumab initiation was 9.8 months. In the subsequent BRAFi ± MEKi group, ORR with previous pembrolizumab was 13.5% (8 PR); 76.3% had discontinued pembrolizumab due to PD; median OS was 17.9 months. ORR with subsequent BRAFi ± MEKi was 30.5%, 7/18 responses (4 CR, 3 PR) were ongoing. Median OS from BRAFi ± MEKi initiation was 12.9 months. ORR for BRAFi ± MEKi-naïve patients who received subsequent BRAFi ± MEKi was 43.2%; 6/16 were ongoing (3 CR, 3 PR). CONCLUSIONS: Ipilimumab and BRAFi ± MEKi have antitumor activity as first subsequent therapy after pembrolizumab in patients with advanced melanoma.
引用
- Long GV, Arance A, Mortier L, et al. Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006. Ann Oncol. 2021. PMID: 34710571. doi:10.1016/j.annonc.2021.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。